Joerg Herrmann MDProfessor of Medicine, Mayo Graduate School of Medicine, Rochester, Minnesota
Dr. Joerg Herrmann received his medical training at Ruhr University, Bochum, Germany, and completed his internship in internal medicine at the University Clinic in Essen. Following a postdoctoral research fellowship, he pursued the clinician–investigator track in internal medicine-cardiology, and further training in interventional cardiology at the Mayo Clinic, Rochester, Minnesota. He then joined the staff of the Department of Cardiovascular Diseases at the Mayo Clinic, Rochester. Currently he is an Associate Professor of Medicine at the Mayo Graduate School of Medicine and serves as the director of the Cardio-Oncology Clinic and the research director of the Ischemic Heart Disease program.
Dr. Herrmann has been receiving NIH research funding, serves as a reviewer for over 30 journals, including all major cardiovascular journals. He is also a contributor to Braunwald’s Heart Disease, the associated editor of Trends in Cardiovascular Medicine, and is the editor of the textbook Clinical Cardio-Oncology.
His main research interests are cardio-oncology, cardiac biomarkers, periprocedural myocardial infarction, atherosclerosis, and vascular biology.
Dr. Joerg Herrmann participated in the 2014 and 2016 Ponatinib in CML Cardio-Oncology Advisory Board meeting organized by ARIAD Pharmaceuticals, the 2016 Carfilzomib Advisory Board meeting organized by Amgen and is a member of the Institute for Cardio-Oncology advisory panel sponsored by Bristol-Myers Squib.
Recent Contributions to PracticeUpdate:
- ESC 2014: Hot Line Picks in Myocardial Infarction
- ESC 2014: Hot Line Picks in Coronary Artery Disease and Atrial Fibrillation
- ESC 2014: Recommendations From the Editorial Board of PracticeUpdate Cardiology
- Statins May Prevent Contrast-Induced Acute Kidney Injury in Coronary Angiography
- Benefit From Surgical Revascularization in LV Dysfunction Depends on Extent of Disease
- Cost-Effectiveness of DES With PCI vs CABG for Patients With Three-Vessel or Left Main Coronary Artery Disease
- Defining Optimal Troponin T Threshold for Predicting Mortality From PCI-Related Myocardial Infarction
- DAPT Offers No Benefit 1 Year After Drug-Eluting Stent Implantation
- Repeat Coronary Angiography in Previously Normal Arteries
- Transradial Access PCI Associated With Reduced Complications/Mortality in Non-STEMI